Tvardi Therapeutics, Inc. (TVRD): Cash & Equivalents
$20.73M
As of 2025-12-31
$15.77M
As of 2026-06-30
| Period ended | Cash & Equivalents | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $20.73M | -34.4% | 2026-03-31, Balance as of period end |
| 2024-12-31 | $31.61M | n/c | 2026-03-31, Balance as of period end |
| 2023-12-31 | $51.77M | -18.8% | 2025-03-11, Balance as of period end |
| 2022-12-31 | $63.74M | +373.8% | 2024-03-06, Balance as of period end |
| 2021-12-31 | $13.45M | -57.5% | 2023-03-06, Balance as of period end |
| 2020-12-31 | $31.68M | +73.1% | 2022-03-01, Balance as of period end |
| 2019-12-31 | $18.30M | +21.4% | 2021-02-25, Balance as of period end |
| 2018-12-31 | $15.08M | +60.6% | 2020-02-27, Balance as of period end |
| 2017-12-31 | $9.39M | -22.4% | 2019-03-12, Balance as of period end |
| 2016-12-31 | $12.09M | -19.9% | 2018-03-15, Balance as of period end |
| 2015-12-31 | $15.10M | -71.3% | 2018-03-15, Balance as of period end |
| 2014-12-31 | $52.66M | +326.2% | 2017-03-10, Balance as of period end |
| 2013-12-31 | $12.36M | n/m | 2016-03-11, Balance as of period end |
| 2012-12-31 | $1.12M | n/a | 2015-03-27, Balance as of period end |
Cash & Equivalents at similar companies
| Company | Year ended | Cash & Equivalents | Change YoY |
|---|---|---|---|
| Tvardi Therapeutics, Inc. (TVRD) | 2025-12-31 | $20.73M | -34.4% |
| Equillium, Inc. (EQ) | 2025-12-31 | $30.28M | +67.4% |
| Nuvectis Pharma, Inc. (NVCT) | 2025-12-31 | $31.63M | +70.7% |
| Dare Bioscience, Inc. (DARE) | 2025-12-31 | $24.71M | +57.4% |
| Valion Bio, Inc. (VBIO) | 2025-12-31 | $12.64M | +531.6% |
| China Pharma Holdings, Inc. (CPHI) | 2025-12-31 | $345.1K | -44.9% |
| PDS Biotechnology Corp (PDSB) | 2025-12-31 | $26.71M | -35.9% |
| Yarrow Bioscience, Inc. (YARW) | 2025-12-31 | $24.03M | +20.6% |
| Sol-Gel Technologies Ltd. (SLGL) | 2025-12-31 | $11.03M | -43.4% |
Compare TVRD, EQ, NVCT, DARE side by side · Screen every company in Pharmaceutical Preparations ↗